BAY-293 is primarily researched for its potential application in the field of medicinal chemistry, particularly as an inhibitor targeting specific protein-protein interactions. Its development is focused on modulating pathways involved in diseases such as cancer, where disrupting these interactions can halt tumor growth or metastasis. In preclinical studies, BAY-293 has shown promise in selectively binding to certain proteins, making it a candidate for further investigation in targeted therapies. Additionally, it is being explored for its role in understanding cellular signaling mechanisms, which could lead to the identification of new therapeutic targets. Its application is still largely experimental, with ongoing studies aimed at optimizing its efficacy and safety profile for potential clinical use.